Enliven Therapeutics

Enliven Therapeutics

Yahoo Finance • 21 days ago

10 mid-cap healthcare stocks with the strongest momentum grades

Mid-cap U.S. healthcare stocks have exhibited strong momentum traits year to date, with several names earning A-range momentum grades that indicate stronger price performance trends relative to sector peers. Seeking Alpha's Quant Momentum... Full story

Yahoo Finance • last month

Miners And More Lead Slew Of Stocks To Watch — With This Line In Focus

Miners like Southern Copper and Newmont lead this screen of stocks to watch in or near buy range alongside UBS, Garmin and more. Continue Reading... Full story

Yahoo Finance • 3 months ago

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Lori Anne Kunkel, Director of Enliven Therapeutics (NASDAQ:ELVN), reported the sale of 10,000 shares of common stock for a total consideration of approximately $345,000 on June 5, 2026, according to a SEC Form 4 filing. Transaction summar... Full story

Yahoo Finance • 3 months ago

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

On June 22, 2026, Orbimed Advisors, a 10% Owner of Enliven Therapeutics, Inc. (NASDAQ:ELVN), disclosed the indirect sale of 860,123 shares for a total transaction value of approximately $39.0 million, as reported in the SEC Form 4 filing.... Full story

Yahoo Finance • 4 months ago

Toll Brothers upgraded, Lennar downgraded: Wall Street's top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Keefe Bruyette upgraded Toll Brothers(... Full story

Yahoo Finance • 4 months ago

This $5.5 Million Exit Raises Questions After Wave Life Sciences' Rough First Quarter

On May 15, 2026, Exome Asset Management reported selling out of Wave Life Sciences(NASDAQ:WVE), liquidating 421,488 shares in an estimated $5.49 million trade based on quarterly average pricing. What happened According to an SEC filing d... Full story

Yahoo Finance • 5 months ago

Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120%

Key Points Avidity Partners added 259,700 shares of Enliven Therapeutics in the first quarter; the estimated transaction value was $7.19 million (based on quarterly average pricing). The quarter-end position value increased by $14.33 mill... Full story

Yahoo Finance • 5 months ago

Why is Enliven Therapeutics (ELVN) One of the Best Performing Healthcare Stocks so Far in 2026?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the best performing healthcare stocks so far in 2026. On April 30, Mizuho reaffirmed an Outperform rating on Enliven Therapeutics, Inc. (NASDAQ:ELVN), setting a price target of $45. The ra... Full story

Yahoo Finance • 6 months ago

Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market

Enliven Therapeutics Inc. (NASDAQ:ELVN) is one of the 11 Stocks With 3x-5x Returns This Year. Enliven Therapeutics has seen its stock price soar by 194 percent year-to-date, at $45.34 versus $15.40 on December 31, with investor sentiment... Full story

Yahoo Finance • 6 months ago

Enliven (ELVN) Gets Higher Price Targets From H.C. Wainwright and Mizuho

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is one of the 10 Best Performing Stocks of Q1 2026 to Watch for Q2. On March 26, H.C. Wainwright increased its price target on Enliven Therapeutics, Inc. (NASDAQ:ELVN) from $48 to $56 and kept its B... Full story

Yahoo Finance • 6 months ago

Enliven Theraeutics' (ELVN) Chief Medical Officer Sold 40,000 Shares for $1.2 Million

Helen Louise Collins, Chief Medical Officer of Enliven Therapeutics(NASDAQ:ELVN), reported the exercise of 40,000 stock options for Common Stock and immediate sale of those shares for proceeds of approximately ~$1.20 million, according to... Full story

Yahoo Finance • 10 months ago

Terns Stock Surges 300% in One Year — What a New $43 Million Position Signals for Investors

Key Points New York City-based Commodore Capital initiated a stake of 5.7 million shares of Terns Pharmaceuticals in the third quarter, an increase of $42.8 million in position value. The new position represents 2.1% of 13F reportable ass... Full story

Yahoo Finance • last year

What's going on in today's pre-market session

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMME... Full story

Yahoo Finance • last year

Terns Pharmaceuticals’ SWOT analysis: obesity drug stock poised for pivotal data

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and other metabolic diseases. The company’s stock has garnered significant attention from analysts and inv... Full story

Yahoo Finance • last year

Enliven files automatic mixed securities shelf

* Enliven Therapeutics (NASDAQ:ELVN [https://seekingalpha.com/symbol/ELVN]) filed automatic mixed securities shelf. * Filing [https://seekingalpha.com/filing/10301128] MORE ON ENLIVEN THERAPEUTICS * Enliven Therapeutics stock falls... Full story

Yahoo Finance • last year

Enliven Therapeutics, Inc Q2 Loss Climbs

(RTTNews) - Enliven Therapeutics, Inc (ELVN) revealed Loss for its second quarter of -$25.34 million The company's bottom line totaled -$25.34 million, or -$0.49 per share. This compares with -$19.95 million, or -$0.41 per share, last ye... Full story

Yahoo Finance • last year

Enliven Therapeutics CSO sells $278k in shares

Joseph P Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.31 billion market cap biotechnology company, sold a total of 12,500 shares of common stock on July 21, 2025, according to a Form 4 filing with... Full story

Yahoo Finance • last year

Enliven Therapeutics COO Patel sells shares worth $131950

Anish Patel, Chief Operating Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), a $1.28 billion market cap biotech company with strong financial health metrics according to InvestingPro, sold shares of the company’s common stock on July... Full story

Yahoo Finance • last year

TD Cowen reiterates buy rating on Enliven Therapeutics stock

Investing.com - TD Cowen maintained its buy rating on Enliven Therapeutics (NASDAQ:ELVN) stock in a research note released Friday. The $1.29 billion market cap company, which has received a strong buy consensus from analysts with price tar... Full story

Yahoo Finance • last year

Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data

Enliven Therapeutics, Inc. (NASDAQ:ELVN) is among the best NASDAQ stocks under $50 to buy. On Monday, analysts at Goldman Sachs started coverage on Enliven Therapeutics, Inc. (NASDAQ:ELVN) with a Buy rating and a $37.00 price target, imply... Full story